Decibel Therapeutics, Inc.

Decibel Therapeutics, Inc. (DBTX) priced its initial public offering on Feb 12, 2021 at $18.00 per share, within its $16.00–$18.00 range, raising $127.1M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $437.4M. Citigroup was lead-left underwriter, joined by Leerink Partners, BMO Capital Markets and Barclays. WilmerHale advised the company and Goodwin Procter advised the underwriters.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for hearing and balance disorders by restoring and regenerating inner ear cells. Its lead gene therapy candidate, DB-OTO, is designed to provide hearing to people born with a congenital, monogenic form of hearing loss.

Status

IPO

Ticker

DBTX

Exchange

Nasdaq Global Select

Priced

Feb 12, 2021

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$127.1M

Market cap at IPO price

$437.4M

First filed

Jan 22, 2021

Underwriters

Citigroup, Leerink Partners, BMO Capital Markets and Barclays

Company counsel

WilmerHale

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.